# The Hidden Cardiomyopathy: Diagnostic Challenges in Confirmed AL (Lambda) Cardiac Amyloidosis Presenting as Cirrhotic Ascites *A Clinical Case Report and Educational Review — Case Closed: Patient Deceased March 4, 2026* **Medical Associates Department of Nephrology \| University of Illinois College of Medicine at Peoria \| University of Dubuque Physician Assistant Program \| UDPA Butler School of Medicine** **Andrew Bland, MD** ------------------------------------------------------------------------ ## Executive Summary > **Key Points** - Cardiac amyloidosis — including both AL (light chain) and ATTR subtypes — is an underdiagnosed cause of heart failure with preserved ejection fraction (HFpEF); this case ultimately confirmed **AL amyloidosis of the lambda variety** (1,2) - Ejection fraction is a profoundly misleading metric in infiltrative cardiomyopathies; a “normal” EF can mask critically reduced cardiac output (1,3) - Congestive hepatopathy from cardiac amyloidosis can mimic cirrhosis on CT imaging, leading to diagnostic misdirection (4) - Ascitic fluid analysis — specifically the combination of high SAAG (≥1.1) and high fluid protein (≥2.5 g/dL) — provides a critical physiologic clue pointing toward cardiac rather than hepatic etiology (5) - The ATTR workup (Tc-99m PYP scintigraphy) returned **negative** in this patient; the **positive monoclonal protein screen and elevated lambda free light chains** raised concern for AL and required tissue confirmation/typing (6) - AL cardiac amyloidosis carries a worse prognosis than ATTRwt; median survival without treatment is 6–12 months from diagnosis in advanced cardiac disease (9) - **Tragic outcome:** This patient died on **March 4, 2026** from sudden cardiac arrest while undergoing staging PET scan — the hemodynamic severity documented on RHC (CI 1.15, RA 23 mmHg) presaged a high risk of sudden arrhythmic death ------------------------------------------------------------------------ ## 1. Case Presentation A 75-year-old male with no known liver disease risk factors presented with progressive abdominal distension and refractory ascites. He had no history of alcohol use, viral hepatitis, nonalcoholic steatohepatitis, or autoimmune liver disease. Notably, he had no lower extremity edema despite massive ascites — an atypical finding that initially did not raise suspicion for a cardiac etiology. ### Initial Workup **Imaging:** - CT abdomen: Micronodular liver changes, multiple hepatic cysts, and findings reported as “cirrhosis with portal hypertension” - Echocardiogram: Ejection fraction (EF) 55%, right ventricular systolic pressure (RVSP) 40 mmHg **Laboratory Data:** - Total bilirubin: 1.7 mg/dL - Serum albumin: 4.0 g/dL - Serum total protein: 6.8 g/dL - INR: ~4.0 on admission (on chronic warfarin therapy) - Note: Patient was anticoagulated with warfarin (Coumadin), rendering the INR uninterpretable as a marker of hepatic synthetic function **Paracentesis:** - Volume removed: 5.7 liters (initial drainage, with rapid reaccumulation requiring repeat paracentesis) - Ascitic fluid protein: 3.6 g/dL (repeat: 4.1 g/dL) - Ascitic fluid albumin: 2.3 g/dL - **Calculated SAAG: 1.7 g/dL** (serum albumin 4.0 − ascitic albumin 2.3) **Diuretic Regimen (refractory):** - Bumetanide (Bumex) 4 mg PO BID — a remarkably high dose of a potent loop diuretic - Dapagliflozin (Farxiga) 10 mg daily — SGLT2 inhibitor providing osmotic diuresis - Spironolactone (Aldactone) 50 mg daily — mineralocorticoid receptor antagonist Despite this aggressive three-agent regimen targeting multiple nephron segments, ascites continued to reaccumulate rapidly. The 5.7-liter paracentesis volume with prompt recurrence despite bumetanide 4 mg PO BID (equivalent to approximately furosemide 320 mg daily) signals profound diuretic resistance — a hallmark of severely compromised cardiac output and elevated right-sided filling pressures. ### The Diagnostic Pivot The hepatology service initially evaluated the patient and concluded that the ascites was **cardiac in origin** despite what appeared to be a benign cardiac evaluation. This assessment was initially met with skepticism — the echo looked relatively reassuring. However, the clinical picture warranted further investigation, and a right heart catheterization was performed. **Right Heart Catheterization:** | Parameter | Value | Normal Range | |------------------------------------|---------------|------------------| | Right atrial pressure (RA) | 23 mmHg | 0–8 mmHg | | RV pressure | 43/25 mmHg | 15–30/0–8 mmHg | | Pulmonary artery pressure | 54/34 mmHg | 15–30/4–12 mmHg | | Pulmonary capillary wedge pressure | 28 mmHg | 4–12 mmHg | | Cardiac output | 2.66 L/min | 4.0–8.0 L/min | | Cardiac index | 1.15 L/min/m² | 2.5–4.0 L/min/m² | | RA oxygen saturation | 64% | 65–75% | | PA oxygen saturation | 65% | 65–75% | **Calculated Hemodynamics:** - Transpulmonary gradient (TPG): 13 mmHg (mean PA 41 − wedge 28) - Diastolic pulmonary gradient (DPG): 6 mmHg (PA diastolic 34 − wedge 28) - Classification: Combined pre- and post-capillary pulmonary hypertension (Cpc-PH) ### The Hemodynamic Revelation The right heart catheterization exposed a dramatic disparity between the echocardiographic appearance and the true hemodynamic state. An EF of 55% with a cardiac index of 1.15 L/min/m² represents **cardiogenic shock-range low output** masked by a preserved ejection fraction. The RA pressure of 23 mmHg fully explains the massive, diuretic-refractory ascites and congestive hepatopathy. ### Step-by-Step Hemodynamic Calculation Walkthrough The following section provides a detailed, calculation-by-calculation walkthrough of how to derive clinically meaningful information from the raw hemodynamic measurements. This is the process that every clinician should perform mentally (or on paper) when interpreting any right heart catheterization. **Raw Measured Data:** | Parameter | Value | Normal Range | |-------------------------------------------|---------------|------------------| | Right atrial pressure (RA) | 23 mmHg | 0–8 mmHg | | RV systolic pressure (RVSP) | 43 mmHg | 15–30 mmHg | | RV end-diastolic pressure (RVEDP) | 25 mmHg | 0–8 mmHg | | PA systolic pressure (PASP) | 54 mmHg | 15–30 mmHg | | PA diastolic pressure (PADP) | 34 mmHg | 4–12 mmHg | | Pulmonary capillary wedge pressure (PCWP) | 28 mmHg | 4–12 mmHg | | Cardiac output (CO) | 2.66 L/min | 4.0–8.0 L/min | | Cardiac index (CI) | 1.15 L/min/m² | 2.5–4.0 L/min/m² | | RA oxygen saturation | 64% | 65–75% | | PA oxygen saturation (SvO₂) | 65% | 65–75% | ------------------------------------------------------------------------ **Calculation 1: Mean Pulmonary Artery Pressure (mPAP)** The mPAP is the average pressure in the pulmonary artery across the cardiac cycle. Because diastole is longer than systole, the mean is weighted toward the diastolic value: > **Formula:** mPAP = (PASP + 2 × PADP) / 3 > **This patient:** mPAP = (54 + 2 × 34) / 3 = (54 + 68) / 3 = 122 / 3 = **40.7 mmHg** **Interpretation:** The 2022 ESC/ERS definition of pulmonary hypertension is mPAP \> 20 mmHg. This patient’s mPAP of 40.7 mmHg is more than double the threshold. This is not borderline — it is moderately severe pulmonary hypertension. Normal mPAP is 10–20 mmHg. ------------------------------------------------------------------------ **Calculation 2: Does the Patient Have Pulmonary Hypertension?** > **Criterion:** mPAP \> 20 mmHg? **YES** (40.7 mmHg) > > **Conclusion: This patient has pulmonary hypertension.** The next step is classification — what type of PH, and what is causing it? ------------------------------------------------------------------------ **Calculation 3: Pre-Capillary vs. Post-Capillary Classification** The PCWP determines whether the elevated PA pressures originate from the pulmonary vasculature itself (pre-capillary) or from backpressure transmitted from the left heart (post-capillary): > **Criterion:** PCWP \> 15 mmHg indicates post-capillary PH (elevated left-sided pressures) > > **This patient:** PCWP = **28 mmHg** → Well above 15 mmHg **Interpretation:** The PCWP of 28 mmHg immediately establishes that this is **post-capillary pulmonary hypertension** — the elevated PA pressures are driven, at least in part, by elevated left atrial pressure transmitted backward from the stiff left ventricle. This rules out Group 1 PAH, Group 3 (lung disease), Group 4 (CTEPH), and Group 5 (multifactorial) as the primary classification. **This is Group 2 PH — pulmonary hypertension due to left heart disease.** ------------------------------------------------------------------------ **Calculation 4: Transpulmonary Gradient (TPG)** The TPG measures the total pressure drop across the pulmonary vascular bed — from the pulmonary artery to the left atrium: > **Formula:** TPG = mPAP − PCWP > **This patient:** TPG = 40.7 − 28 = **12.7 mmHg** **Interpretation:** Normal TPG is \< 12 mmHg. A TPG of 12.7 mmHg is mildly elevated, suggesting that not all of the elevated PA pressure is passively transmitted from the left heart. There is an additional component — the pulmonary vasculature itself is contributing resistance beyond what passive congestion would explain. ------------------------------------------------------------------------ **Calculation 5: Diastolic Pulmonary Gradient (DPG)** The DPG is a more specific marker of intrinsic pulmonary vascular disease than the TPG because it is less affected by cardiac output and flow: > **Formula:** DPG = PADP − PCWP > **This patient:** DPG = 34 − 28 = **6 mmHg** **Interpretation:** A DPG ≥ 7 mmHg is the traditional threshold for identifying a pre-capillary component superimposed on post-capillary PH. This patient’s DPG of 6 mmHg is borderline — just below the threshold, but functionally elevated. The DPG should be interpreted alongside the PVR (see below) rather than in isolation. ------------------------------------------------------------------------ **Calculation 6: Pulmonary Vascular Resistance (PVR)** The PVR is the primary measure of the resistive load the right ventricle must overcome to push blood through the pulmonary vasculature. It is the most clinically consequential derived parameter for PH classification: > **Formula:** PVR = (mPAP − PCWP) / CO, expressed in Wood units (WU) > **This patient:** PVR = (40.7 − 28) / 2.66 = 12.7 / 2.66 = **4.8 Wood units** **Interpretation:** The 2022 ESC/ERS threshold for pre-capillary PH is PVR \> 2 WU (previously ≥ 3 WU). This patient’s PVR of 4.8 WU substantially exceeds this threshold, indicating significant pulmonary vascular resistance beyond passive congestion. This means the pulmonary vasculature has undergone structural remodeling — the chronically elevated left-sided pressures have been transmitted backward long enough to cause intimal fibrosis and medial hypertrophy in the pulmonary arterioles. ------------------------------------------------------------------------ **Calculation 7: Final PH Classification — IpcPH vs. CpcPH** Within Group 2 PH (left heart disease), the PVR further subclassifies the hemodynamic pattern: > **Isolated post-capillary PH (IpcPH):** mPAP \> 20, PCWP \> 15, PVR ≤ 2 WU → passive congestion only > > **Combined pre/post-capillary PH (CpcPH):** mPAP \> 20, PCWP \> 15, PVR \> 2 WU → passive congestion PLUS pulmonary vascular remodeling > > **This patient:** mPAP 40.7 (\> 20) ✓, PCWP 28 (\> 15) ✓, PVR 4.8 (\> 2 WU) ✓ > **Final Classification: Group 2 CpcPH — Combined Pre- and Post-Capillary Pulmonary Hypertension Due to Left Heart Disease (Restrictive Cardiomyopathy from Suspected ATTR Amyloidosis)** ------------------------------------------------------------------------ **Calculation 8: Pulmonary Arterial Compliance (PAC)** PAC measures the capacitive (pulsatile) component of RV afterload — how much the pulmonary artery can stretch to accommodate each stroke volume: > **Formula:** PAC = Stroke Volume / (PASP − PADP) > **Stroke Volume:** CO / HR. If we estimate HR at ~80 bpm: SV = 2660 mL/min ÷ 80 = **33 mL** (critically reduced; normal ~70 mL) > **This patient:** PAC = 33 / (54 − 34) = 33 / 20 = **1.65 mL/mmHg** **Interpretation:** Normal PAC is \> 2.3 mL/mmHg. This patient’s PAC of 1.65 mL/mmHg is reduced, indicating stiff, noncompliant pulmonary arteries. Reduced PAC is an independent predictor of mortality in PH and provides prognostic information beyond PVR alone. It confirms that the pulmonary vasculature has undergone structural changes that make it less able to buffer the pulsatile RV output. ------------------------------------------------------------------------ **Calculation 9: PCWP − RVEDP Gradient (Restriction vs. Constriction)** This gradient differentiates restrictive cardiomyopathy from constrictive pericarditis: > **Formula:** PCWP − RVEDP (using PCWP as surrogate for LVEDP) > **This patient:** 28 − 25 = **+3 mmHg** **Interpretation:** In restrictive cardiomyopathy, left-sided filling pressures typically exceed right-sided by \> 5 mmHg because the LV (with more myocardial mass) is stiffer from amyloid infiltration. In constrictive pericarditis, the rigid pericardium constrains both ventricles equally, so pressures equalize within 5 mmHg. This patient’s gradient of +3 mmHg is in the “equalization zone” (≤ 5 mmHg), which might initially suggest constriction. However, the direction is correct for restriction (left exceeds right), and the narrow gap reflects the severity of biventricular disease — both ventricles are heavily infiltrated at this advanced stage. Earlier in the disease course, the gradient would be wider (e.g., PCWP 22 / RVEDP 12 = +10 mmHg). The clinical context (75-year-old male, increased wall thickness, no pericardial disease risk factors, EF–CO dissociation) overwhelmingly favors restrictive cardiomyopathy over constriction. ------------------------------------------------------------------------ **Calculation 10: RVEDP/RVSP Ratio** > **Formula:** RVEDP / RVSP > **This patient:** 25 / 43 = **0.58** **Interpretation:** A ratio \> 1/3 (0.33) has traditionally been cited as favoring constriction (where pericardial constraint limits RV systolic pressure generation while elevating RVEDP). This patient’s ratio of 0.58 substantially exceeds 1/3. However, this criterion is unreliable in severe restrictive disease with profoundly elevated RVEDP. The very high ratio reflects the severity of biventricular diastolic dysfunction, not pericardial constraint. The RVSP of 43 mmHg is consistent with the moderate pulmonary hypertension present — the RV is generating appropriate pressure to overcome the elevated PVR. ------------------------------------------------------------------------ **Calculation 11: Forrester Profile Classification** The Forrester classification uses two parameters to define the hemodynamic profile: > **PCWP \> 18 mmHg** → “Wet” (congested): **YES** (28 mmHg) > > **CI \< 2.2 L/min/m²** → “Cold” (hypoperfused): **YES** (1.15 L/min/m²) > **Classification: Forrester Profile C — “Cold and Wet”** (congested AND hypoperfused) **Interpretation:** Profile C carries the worst prognosis of all hemodynamic subsets. The patient has both volume overload (driving the ascites, hepatic congestion, and elevated filling pressures) and inadequate forward perfusion (driving the renal hypoperfusion, low SvO₂, and diuretic resistance). Treatment requires simultaneous decongestion and hemodynamic support — diuretics alone cannot solve the problem because the cardiac output is insufficient to deliver the diuretic to the kidney effectively, and the low output drives neurohormonal activation that counteracts the diuretic effect. ------------------------------------------------------------------------ **Calculation 12: Mixed Venous Oxygen Saturation Assessment** > **Measured SvO₂ (PA saturation):** 65% **Interpretation:** Normal SvO₂ is 65–75%. This patient is at the absolute lower limit of normal, indicating that the body is extracting a higher-than-normal proportion of delivered oxygen to compensate for the critically low cardiac output. An SvO₂ of 65% with a CI of 1.15 L/min/m² means the tissues are barely maintaining oxygen balance. Any further decline in CO — from arrhythmia, infection, dehydration, or disease progression — would push the SvO₂ below 60% into the range associated with anaerobic metabolism, lactic acidosis, and end-organ failure. ------------------------------------------------------------------------ **Calculation 13: Stroke Volume and EF–CO Dissociation** > **Stroke Volume (SV):** CO / HR = 2660 / ~80 = **~33 mL** (normal ~70 mL) > > **If EF is 55%:** SV = EF × End-Diastolic Volume → 33 = 0.55 × EDV → EDV = 33 / 0.55 = **~60 mL** (normal ~120 mL) **Interpretation:** The left ventricle is filling to approximately 60 mL (half the normal end-diastolic volume) because the amyloid-infiltrated walls are so stiff that the chamber cannot expand. It then ejects 55% of this tiny volume — appearing “normal” on echocardiography — while delivering a stroke volume that is less than half of what a healthy heart produces. This is the fundamental mechanism by which preserved EF conceals hemodynamic devastation in infiltrative cardiomyopathy. ------------------------------------------------------------------------ ### Summary of Derived Hemodynamic Parameters | Derived Parameter | Calculation | Result | Normal | Clinical Significance | |----|----|----|----|----| | mPAP | (54 + 2×34) / 3 | 40.7 mmHg | 10–20 | Confirms PH (moderately severe) | | TPG | 40.7 − 28 | 12.7 mmHg | \< 12 | Mildly elevated; pre-capillary component present | | DPG | 34 − 28 | 6 mmHg | \< 7 | Borderline; approaching threshold for CpcPH | | PVR | 12.7 / 2.66 | 4.8 WU | 0.25–1.6 | Substantially elevated; confirms CpcPH | | PAC | ~33 / 20 | 1.65 mL/mmHg | \> 2.3 | Reduced; stiff pulmonary vasculature | | PCWP − RVEDP | 28 − 25 | +3 mmHg | N/A | Left exceeds right (direction favors RCM); narrow gap reflects advanced biventricular disease | | RVEDP/RVSP | 25 / 43 | 0.58 | N/A | Elevated from severe biventricular diastolic dysfunction, not pericardial constraint | | Stroke volume | 2660 / ~80 | ~33 mL | ~70 mL | Critically reduced; explains the EF–CO dissociation | | Estimated EDV | 33 / 0.55 | ~60 mL | ~120 mL | Severely reduced; the stiff ventricle cannot fill | | Forrester profile | PCWP \> 18, CI \< 2.2 | Profile C | A | “Cold and wet” — worst hemodynamic subset | ### Final Hemodynamic Diagnosis This right heart catheterization establishes: 1. **Pulmonary hypertension — Group 2, CpcPH:** mPAP 40.7 mmHg with PCWP 28 mmHg and PVR 4.8 WU, indicating left heart disease (restrictive cardiomyopathy from suspected ATTR amyloidosis) with superimposed pulmonary vascular remodeling from chronically elevated left-sided pressures. 2. **Restrictive physiology consistent with infiltrative cardiomyopathy:** EF–CO dissociation (55% EF with CI 1.15), PCWP exceeding RVEDP (correct direction for restriction), severely elevated biventricular filling pressures. 3. **Cardiogenic shock-range hemodynamic compromise:** CI 1.15 L/min/m², SvO₂ 65%, estimated stroke volume ~33 mL — all indicating critically inadequate forward perfusion. 4. **Forrester Profile C (“cold and wet”):** Simultaneously congested (PCWP 28) and hypoperfused (CI 1.15) — the hemodynamic profile with the worst prognosis, requiring simultaneous decongestion and hemodynamic support. 5. **Hemodynamic explanation for diuretic resistance:** RA 23 mmHg → renal venous congestion → impaired diuretic tubular secretion and reduced filtration fraction; CI 1.15 → renal hypoperfusion → reduced diuretic delivery to the kidney; dual compromise overwhelms triple nephron blockade (bumetanide 4 mg BID + dapagliflozin + spironolactone). ### Treatment Implications of the PH Classification The Group 2 CpcPH classification has direct therapeutic consequences: **PAH-specific vasodilator therapy is NOT indicated.** Despite the elevated PVR of 4.8 WU, this patient does not have Group 1 PAH. Endothelin receptor antagonists, PDE5 inhibitors, and prostanoids are contraindicated in Group 2 PH because they increase pulmonary blood flow into an already congested left heart, worsening pulmonary edema and heart failure without reducing mortality. Misclassification of Group 2 as Group 1 is one of the most dangerous diagnostic errors in pulmonary hypertension management. **Disease-modifying therapy targeting the underlying cardiomyopathy is the primary intervention.** If tafamidis or acoramidis can stabilize the amyloid-infiltrated myocardium, the resulting improvement in LV compliance should reduce PCWP, which in turn reduces the passive component of pulmonary hypertension. Over time, some degree of reverse pulmonary vascular remodeling may occur as the left-sided pressures normalize — though the fixed structural component (PVR 4.8 WU) may not fully resolve. **Decongestion remains essential but must be pursued carefully.** The profoundly low CI means that aggressive diuresis risks further reducing preload below the threshold needed to maintain even the marginal cardiac output. In restrictive physiology, the ventricle operates on a steep, unfavorable portion of the Frank-Starling curve — small reductions in preload produce large drops in stroke volume. The goal is to reduce congestion enough to relieve symptoms (ascites, hepatopathy) while maintaining sufficient preload to support forward output. This requires hemodynamic-guided titration, which is one of the primary indications for serial RHC monitoring in advanced heart failure. ------------------------------------------------------------------------ ## 2. The Diagnostic Red Herrings ### Red Herring \#1: The CT “Cirrhosis” The CT findings of micronodular liver changes were initially interpreted as cirrhosis. However, chronic hepatic venous congestion from elevated right-sided pressures can produce **cardiac pseudo-cirrhosis** — a nodular liver appearance caused by centrilobular necrosis and patchy regeneration that mimics true cirrhotic remodeling on imaging (4). Without a clear etiology for cirrhosis, this should have prompted consideration of congestive hepatopathy. ### Red Herring \#2: The “Normal” Ejection Fraction — The Single Most Dangerous Cognitive Trap in Cardiac Amyloidosis Diagnosis The echocardiographic EF of 55% created a false sense of reassurance that nearly derailed the diagnostic process. This is not an isolated failure of clinical reasoning — it is a well-documented, literature-validated phenomenon that represents the single most important barrier to timely diagnosis of cardiac amyloidosis worldwide. **Recognizing the cause of HFpEF:** Cardiac amyloidosis can be overlooked when symptoms and increased wall thickness are attributed to aging or hypertension. The [2020 AHA scientific statement](https://pubmed.ncbi.nlm.nih.gov/32476490/) recommends assessing compatible cardiac and extracardiac findings. Prevalence estimates from selected screening cohorts should not be generalized to every person with HFpEF. **Diagnostic delay:** [Ladefoged et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32033783/) reviewed 50 patients with ATTRwt at one center. Median delay was 13 months, and longer delay was associated with more advanced symptoms and diastolic dysfunction at diagnosis. This observational association does not establish that delay caused the difference. **Diagnostic awareness:** AL and ATTR amyloidosis require different evaluation and treatment. Unexplained wall thickening, proteinuria, neuropathy, or a discordant cardiac phenotype should prompt assessment rather than a nonspecific cardiomyopathy label. [AL amyloidosis review](https://pubmed.ncbi.nlm.nih.gov/36444232/). **Screening practice:** [Shchendrygina et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39481586/) surveyed 1,460 physicians from 95 countries. Ten percent reported systematic screening of all patients with HFpEF and 24% did not consider screening. This voluntary physician survey describes respondents’ practice and is not a representative estimate of the proportion of patients screened worldwide. **Why the EF is specifically misleading in amyloid.** In infiltrative cardiomyopathies, the ventricle is thick, stiff, and small. It cannot fill properly, but the percentage of its reduced volume that is ejected appears normal. A simple illustration: - Normal heart: fills 120 mL, ejects 80 mL → EF 67% - Amyloid heart: fills 50 mL, ejects 28 mL → EF 55% The EF appears nearly identical, but the cardiac output is catastrophically different. This patient’s numbers prove the point — EF 55% with CI 1.15 L/min/m². The EF of 55% provided false reassurance to every clinician who reviewed the echocardiogram. The cardiac index of 1.15 — measured only because the hepatology service had the clinical acumen to push for right heart catheterization — revealed cardiogenic shock-range hemodynamic compromise that was completely invisible to the echocardiographic EF. > **Preserved EF does not exclude cardiac disease.** In a patient with unexplained wall thickening, low cardiac output, restrictive filling, or disproportionate congestion, investigate the cause of HFpEF. Amyloidosis is one consideration; diagnose it through appropriate imaging, monoclonal protein testing, and tissue evaluation when indicated. [ACC consensus](https://pubmed.ncbi.nlm.nih.gov/36697326/). > **Clinical Pearl:** EF measures the *fraction* of blood ejected, not the *volume*. In restrictive physiology, a preserved EF can coexist with critically reduced cardiac output. Global longitudinal strain (GLS) with apical sparing is a more sensitive echocardiographic marker of amyloid infiltration than EF and should be assessed in any patient with HFpEF and unexplained LV hypertrophy. When the clinical picture is worse than the echo suggests, pursue invasive hemodynamic assessment — the RHC will reveal what the echo conceals. ### Red Herring \#3: The Mildly Elevated RVSP An RVSP of 40 mmHg on echocardiography appeared mildly elevated and nonspecific. However, a failing right ventricle may be unable to generate a high TR velocity jet — the echo-estimated RVSP underestimates true pulmonary pressures when the RV is failing. The catheterization revealed PA pressures of 54/34, substantially higher than the echo predicted. ### Red Herring \#4: Absence of Lower Extremity Edema with Massive Ascites The clinical presentation was striking in its distribution: **5.7 liters of ascites with rapid reaccumulation but minimal or absent peripheral edema**. This pattern initially seemed to argue against a cardiac etiology — conventional teaching associates right heart failure with dependent edema, jugular venous distension, and ascites, typically in that order. A patient with “only ascites” is more readily attributed to liver disease. However, in cardiac amyloidosis with severe right-sided congestion, the distribution of fluid accumulation can preferentially involve the splanchnic circulation. With an RA pressure of 23 mmHg, the hepatic venous pressure is massively elevated, creating an enormous hydrostatic gradient favoring fluid transudation across the hepatic sinusoidal bed and into the peritoneal cavity. The splanchnic vascular bed, which receives approximately 25% of cardiac output and has a uniquely permeable sinusoidal endothelium, becomes the path of least resistance for fluid extravasation. Meanwhile, the low cardiac output state (CI 1.15) limits effective arterial perfusion of the extremities, and the severely reduced stroke volume may be insufficient to generate the capillary hydrostatic pressures in lower extremity venous beds required for peripheral edema formation. This patient demonstrated the paradox elegantly: the ascites was massive, refractory, and rapidly recurrent, while the legs remained remarkably dry. The rapid reaccumulation of 5.7 liters within days of paracentesis reflects the relentless hemodynamic driver — an RA pressure of 23 mmHg that does not respond to the oral diuretic regimen — rather than the slow, progressive fluid accumulation of cirrhotic ascites. > **Clinical Pearl:** When ascites is massively out of proportion to peripheral edema, think *cardiac* before *cirrhotic*. The splanchnic circulation is the primary target of right-sided congestion, and preferential ascites formation with minimal pedal edema is a characteristic — not contradictory — pattern in right heart failure from restrictive cardiomyopathy. ### Red Herring \#5: Preserved Hepatic Synthetic Function — and Its Partial Concealment The serum albumin of 4.0 g/dL is remarkably well-preserved for a patient with ascites reportedly due to cirrhosis. True decompensated cirrhosis sufficient to cause massive ascites typically presents with declining synthetic function (albumin \< 3.0, rising bilirubin, coagulopathy). This preserved albumin strongly argues against advanced cirrhotic liver disease as the primary etiology and instead supports the concept that the hepatic parenchyma is structurally intact but hemodynamically congested. However, there is an important nuance in this case: **the patient was on chronic warfarin (Coumadin) therapy with an INR in the 4 range at admission**. This supratherapeutic INR introduces a critical interpretive challenge. The INR — normally a key component of the Model for End-Stage Liver Disease (MELD) score and Child-Pugh classification — is entirely obscured by anticoagulation. An INR of 4.0 on warfarin cannot be attributed to hepatic synthetic failure; it reflects the pharmacologic effect of vitamin K antagonism on factors II, VII, IX, and X, not an inability of the liver to produce these proteins. This matters for two reasons. First, it may have contributed to the initial clinical impression of “cirrhosis with coagulopathy,” artificially inflating the perceived severity of liver disease. A clinician glancing at the labs — ascites, elevated bilirubin, INR of 4.0 — might reasonably calculate a high MELD score and conclude the patient has severe liver dysfunction. But the INR in this context is an artifact of anticoagulation, not a reflection of hepatic failure. Second, it emphasizes the importance of identifying **which synthetic markers are evaluable** in each clinical scenario. In this case, only albumin was interpretable, and its preservation at 4.0 g/dL argues powerfully against cirrhosis as the primary diagnosis. > **Clinical Pearl:** When assessing hepatic synthetic function in anticoagulated patients, the INR is not interpretable. Rely on albumin, total protein, and factor V (which is not vitamin K-dependent) as markers of true hepatic synthetic capacity. An elevated INR on warfarin does not equal hepatic failure, and this distinction can prevent misclassification of cardiac congestion as decompensated cirrhosis. ------------------------------------------------------------------------ ## 3. The Sinusoidal Physiology: Why Ascitic Fluid Protein Matters Understanding why cardiac ascites produces high-protein fluid while cirrhotic ascites produces low-protein fluid requires understanding hepatic sinusoidal architecture. ### Normal Hepatic Sinusoids Liver sinusoids are unique capillaries with a **fenestrated endothelium lacking a basement membrane**. These fenestrations freely permit passage of plasma proteins, including albumin, from the sinusoidal blood into the space of Disse. This means the interstitial fluid surrounding hepatocytes is normally protein-rich. ### In Cirrhosis: Sinusoidal Capillarization Chronic liver disease causes collagen deposition in the space of Disse and development of a basement membrane — a process called **sinusoidal capillarization**. The fenestrations close. The sinusoid now behaves like a typical capillary, restricting protein passage. Combined with elevated portal pressure driving fluid out, the result is **protein-poor ascites** (typically \< 2.5 g/dL), because the damaged barrier will not permit albumin through. ### In Cardiac Congestion: Intact Sinusoids Under Pressure In cardiac ascites, the sinusoidal architecture is **structurally normal**. Fenestrations remain open and permeable. The pathology is purely hemodynamic — elevated hepatic venous pressure (driven by a high RA pressure) backs up into the sinusoids and forces fluid out through an intact, protein-permeable endothelium. The result is **protein-rich ascites** (typically ≥ 2.5 g/dL), because proteins cross the fenestrated sinusoidal wall freely. ### Application to This Case | Parameter | Cirrhotic Ascites | Cardiac Ascites | This Patient | |----|----|----|----| | SAAG | ≥ 1.1 g/dL | ≥ 1.1 g/dL | **1.7 g/dL** | | Ascitic fluid protein | \< 2.5 g/dL | ≥ 2.5 g/dL | **3.6–4.1 g/dL** | | Sinusoidal fenestrations | Closed (capillarized) | Open (intact) | Intact | | Synthetic function | Impaired | Preserved | **Preserved** | The ascitic fluid protein of 3.6–4.1 g/dL indicates that the sinusoidal fenestrations are intact and that the ascites is being produced by hemodynamic congestion, not cirrhotic remodeling. > ⚠️ **Warning:** The ascitic fluid protein cutoff of 2.5 g/dL for differentiating cardiac from cirrhotic ascites has sensitivity and specificity in the 70–80% range and should be interpreted as a Bayesian probability modifier, not a definitive diagnostic test (5). It is the *gestalt* of preserved synthetic function, high-protein ascites, high SAAG, no liver disease risk factors, and hemodynamic data that establishes the diagnosis. ------------------------------------------------------------------------ ## 4. The Unifying Diagnosis: Confirmed AL (Lambda) Cardiac Amyloidosis ### Clinical Reasoning and Final Diagnosis The complete clinical picture — a 75-year-old male with HFpEF, severely elevated biventricular filling pressures, critically reduced cardiac output despite preserved EF, combined pulmonary hypertension, diuretic-refractory cardiac ascites, congestive hepatopathy mimicking cirrhosis, and no liver disease risk factors — was initially highly suspicious for cardiac amyloidosis. The initial differential favored ATTR given the patient’s age and sex. **However, the diagnostic workup revealed a critically important pivot:** - **Tc-99m PYP scintigraphy: NEGATIVE** (Grade 0 — no myocardial uptake above background) — effectively excluding ATTR-CM as the diagnosis per Gillmore 2016 criteria - **Serum protein immunofixation electrophoresis: POSITIVE** — monoclonal lambda protein identified - **Serum free light chains: ABNORMAL** — elevated lambda free light chains with an abnormal kappa/lambda ratio, consistent with a clonal plasma cell disorder - **Final Diagnosis: AL (Lambda) Cardiac Amyloidosis** — light chain amyloidosis with cardiac involvement from a lambda-producing plasma cell clone The positive monoclonal protein screen raises concern for an underlying plasma-cell disorder and possible AL amyloidosis. A negative PYP scan does not establish AL or exclude every form of ATTR. Tissue demonstration of amyloid with appropriate typing is needed to establish AL amyloidosis; the testing summarized here does not document that step. [ACC consensus](https://pubmed.ncbi.nlm.nih.gov/36697326/). > ⚠️ **Critical Teaching Point:** This case vindicates the mandatory step of excluding AL amyloidosis before diagnosing ATTR-CM. The PYP scan cannot be interpreted without monoclonal protein exclusion. Had the clinician seen a slightly elevated PYP uptake and not checked free light chains, tafamidis or acoramidis would have been prescribed for ATTR disease that the patient did not have — while the true AL amyloidosis remained untreated and rapidly lethal. ### Why Amyloid Explains Every Finding | Finding | Mechanism in Amyloid | |----|----| | Preserved EF with low cardiac output | Stiff, infiltrated ventricle fills poorly but ejects a high fraction of its small volume | | RA pressure 23 mmHg | Stiff RV cannot accommodate venous return | | Wedge pressure 28 mmHg | Stiff LV requires enormous filling pressures | | Combined pulmonary hypertension | Chronically elevated left-sided pressures cause vascular remodeling | | CI 1.15 L/min/m² | Severely reduced stroke volume from restrictive filling | | Diuretic-refractory ascites despite bumetanide 4mg BID | Massive RA pressure drives hepatic congestion; CI 1.15 impairs renal perfusion and diuretic delivery; gut edema reduces oral bioavailability | | Rapid reaccumulation of 5.7L after paracentesis | Persistent hemodynamic driver (RA 23) overwhelms renal sodium excretory capacity | | Congestive hepatopathy/“cirrhosis” on CT | Chronic congestion causes centrilobular necrosis and nodular regeneration | | High-protein ascites (3.6–4.1 g/dL) | Intact sinusoidal fenestrations; congestion, not cirrhosis | | Preserved albumin (4.0 g/dL) | Hepatocytes structurally intact; pathology is hemodynamic, not parenchymal | | INR ~4.0 on warfarin | Coagulopathy is pharmacologic (anticoagulation), not hepatic synthetic failure; obscures MELD assessment | | Absent lower extremity edema | Preferential splanchnic congestion; low CO limits peripheral capillary hydrostatic pressure | ------------------------------------------------------------------------ ## 5. Diagnostic Workup: Testing Ordered The following diagnostic studies have been ordered to confirm the suspected diagnosis of Amyloid in diagnosing AL vs ATTR Amyloid ### 5a. Monoclonal Protein Screen (Exclude AL Amyloidosis) **Tests ordered:** - Serum free light chains (kappa and lambda with ratio) - Serum protein immunofixation electrophoresis - Urine protein immunofixation electrophoresis **Rationale:** AL (light chain) amyloidosis must be excluded before interpreting the PYP scan. AL amyloidosis can produce grade 2–3 uptake on bone scintigraphy in approximately 10% of cases, and its treatment (chemotherapy directed at the clonal plasma cell process) is entirely different from ATTR therapy (6,9). A positive PYP scan is only diagnostic of ATTR in the **absence** of a monoclonal protein. > ⚠️ **Warning:** The prevalence of monoclonal gammopathy of undetermined significance (MGUS) increases with age and may coexist with ATTR amyloidosis. If monoclonal protein is detected, endomyocardial biopsy with mass spectrometry-based amyloid typing may be required to definitively determine the amyloid subtype (9). ### 5b. Technetium-99m Pyrophosphate (Tc-99m PYP) Scintigraphy **What it is:** A nuclear medicine study using technetium-labeled bone-seeking tracers that have high affinity for transthyretin amyloid deposits in the myocardium (6). **Procedure:** Tc-99m PYP is injected intravenously. Planar and SPECT images are acquired at 1 and 3 hours. Myocardial uptake is graded by visual comparison to rib uptake and quantified by heart-to-contralateral chest (H/CL) ratio. **Grading (Perugini Scale):** | Grade | Description | Interpretation | |-------|-------------------------|-----------------------------| | 0 | No myocardial uptake | ATTR very unlikely | | 1 | Mild uptake \< rib | Equivocal | | 2 | Uptake equal to rib | Strongly suggestive of ATTR | | 3 | Uptake greater than rib | Diagnostic of ATTR | An **H/CL ratio ≥ 1.5** at 1 hour is also diagnostic. **Diagnostic performance:** In the landmark multicenter study by Gillmore et al. (2016), bone scintigraphy was greater than 99% sensitive and 86% specific for cardiac ATTR amyloidosis, with specificity approaching 100% when AL amyloidosis was excluded by negative monoclonal protein screening (6). **Noninvasive diagnostic criteria for ATTR-CM (6):** Grade 2 or 3 myocardial uptake on Tc-99m PYP/DPD/HMDP scintigraphy **PLUS** absence of monoclonal protein in serum and urine = diagnostic of ATTR-CM without the need for endomyocardial biopsy. ### 5c. Genetic Testing (TTR Gene Sequencing) — and Its Relationship to PYP Scintigraphy **A critical question arises: If TTR gene sequencing identifies a pathogenic variant, does the patient still need PYP scintigraphy?** The answer is nuanced and requires understanding what each test proves: **TTR gene sequencing** identifies whether a pathogenic variant in the TTR gene is present. A positive result confirms the patient carries a hereditary ATTR variant (ATTRv) and is *predisposed* to developing amyloidosis. However, a positive TTR variant alone does **not** prove that the variant has caused cardiac amyloid deposition. Many variant carriers never develop clinically significant cardiac disease, and the variant may be an incidental finding, particularly Val122Ile which has 3–4% carrier frequency in African Americans but incomplete penetrance. Furthermore, a negative TTR gene test does not exclude ATTR-CM — it simply means the patient has wild-type disease (ATTRwt), which is the more common form in males over 65 (1,4). **PYP scintigraphy** demonstrates *cardiac amyloid deposition in the myocardium right now*. It answers a fundamentally different question: not “does this patient have a genetic predisposition?” but “is there transthyretin amyloid physically present in the heart?” This is the critical diagnostic question when the goal is to confirm that cardiac amyloidosis is the cause of the patient’s heart failure (6). TTR genetic testing does not establish cardiac amyloid deposition. An appropriate grade 2–3 bone-tracer scan can support nonbiopsy ATTR-CM only after AL is excluded with the full monoclonal screen. A monoclonal protein or unresolved/discordant imaging generally requires tissue evaluation and reliable typing. Confirmed ATTR then warrants genetic testing to distinguish hereditary from wild-type disease. The complete diagnostic sequence is: 1. **Monoclonal protein screen** → exclude AL amyloidosis 2. **Tc-99m PYP scintigraphy** → confirm cardiac ATTR amyloid deposition (grade 2–3 = diagnostic when monoclonal protein absent) 3. **TTR gene sequencing** → performed after ATTR-CM is confirmed to classify as ATTRwt or ATTRv > **Clinical Pearl:** Think of TTR gene testing as answering “what type?” while PYP scintigraphy answers “is it there?” A positive gene test without PYP confirmation could lead to misattribution of heart failure to amyloidosis when another etiology may be responsible. The PYP scan is the linchpin of the noninvasive diagnostic pathway and cannot be bypassed (6). ### 5d. Diagnostic Results and Clinical Course **Monoclonal Protein Screen Results (completed locally):** - Serum protein immunofixation electrophoresis: **POSITIVE** — lambda monoclonal protein identified - Serum free light chains: **ABNORMAL** — elevated lambda free light chains, abnormal kappa/lambda ratio - Urine protein immunofixation: **POSITIVE** for lambda light chains **Tc-99m PYP Scintigraphy (UIHC referral):** - The patient was referred to the University of Iowa Hospitals and Clinics for Tc-99m PYP scintigraphy. - Result: **NEGATIVE** — Grade 0 uptake; no myocardial tracer uptake above background - This definitively excluded ATTR-CM as the diagnosis **Synthesis:** Positive lambda monoclonal protein testing with negative PYP scintigraphy warrants urgent hematologic evaluation and tissue confirmation with amyloid typing. These tests alone cannot confirm AL cardiac amyloidosis. AL was the reported clinical diagnosis in this case, but no tissue-typing result is presented here. **Staging PET Scan:** The patient was scheduled for a staging FDG-PET scan as part of his AL amyloidosis hematologic workup (to evaluate for bone marrow plasma cell burden and systemic disease extent). He died during this procedure on **March 4, 2026** (see Section 9, Clinical Outcome). ------------------------------------------------------------------------ ## 6. Anticipated Treatment > **Note on Treatment Planning:** This section reflects the treatment that would have been initiated had the patient survived to receive it. He died on March 4, 2026, before systemic therapy could be started (see Section 9). ### 6a. Disease-Modifying Therapy for AL (Lambda) Cardiac Amyloidosis **The therapeutic strategy for AL amyloidosis is fundamentally different from ATTR-CM.** Tafamidis and acoramidis — which target the TTR tetramer — have no role in AL amyloidosis. The treatment of AL amyloidosis targets the **underlying plasma cell clone** that produces the amyloidogenic lambda light chains. Eliminating or reducing the clonal source of light chain production is the only way to stop ongoing amyloid deposition and allow the body’s limited capacity for fibril clearance to improve organ function. **Cardiac AL Amyloidosis Prognosis and Urgency** Do not merge amyloid staging systems. Mayo 2012 uses measured dFLC, a specified troponin assay, and NT-proBNP. The European modification of the earlier cardiac system subdivides stage III using NT-proBNP above 8,500 ng/L. Blood pressure, cardiac index, and right-atrial pressure inform clinical severity but do not substitute for the defining biomarkers or establish stage IIIB. The very low cardiac index and elevated filling pressures indicate severe hemodynamic compromise. They do not assign Mayo stage IIIB. Obtain the required assay-specific biomarkers and establish amyloid type before attaching a formal stage or stage-specific survival estimate. **Daratumumab-Based Regimens (Current Standard of Care)** The [ANDROMEDA trial (2021)](https://pubmed.ncbi.nlm.nih.gov/34192431/) compared daratumumab plus bortezomib, cyclophosphamide, and dexamethasone with the latter three drugs in newly diagnosed AL amyloidosis. Hematologic complete response was 53.3% versus 18.1%, with more cardiac and renal responses at six months. Treatment requires specialist selection and adjustment to organ function; these findings do not guarantee recovery for an individual patient. For this patient with severe cardiac compromise (CI 1.15, RA 23 mmHg), treatment would require: - **Hematology consultation** for plasma cell dyscrasia evaluation and treatment planning - **Bone marrow biopsy** with Congo red stain, mass spectrometry amyloid typing confirmation, and plasma cell percentage quantification - **Careful Dara-VCd dosing** with dose modifications for hemodynamic fragility (standard dexamethasone may require reduction in advanced cardiac disease) - **Avoid carfilzomib** (cardiotoxic) and melphalan-based conditioning (due to hemodynamic instability precluding autologous stem cell transplant in this stage) **Autologous Stem Cell Transplant (ASCT)** ASCT achieves the highest rates of complete hematologic response and is the most effective treatment when feasible, but it is contraindicated in patients with advanced cardiac disease such as this patient (CI 1.15 and RA 23 mmHg; formal amyloid stage unconfirmed). Cardiac transplantation followed by subsequent ASCT is an emerging strategy at specialized centers for young patients with isolated cardiac AL amyloidosis, but is not applicable here given age and disease severity. ### 6b. Heart Failure Management Considerations > ⚠️ **Warning:** Standard HFpEF medications require careful consideration in cardiac amyloidosis: - **Beta-blockers and calcium channel blockers** may be poorly tolerated or harmful. The stiff amyloid ventricle is rate-dependent for cardiac output — slowing heart rate further reduces already compromised output. These agents should be discontinued or avoided if possible (1,9). - **ACE inhibitors/ARBs** may cause significant hypotension due to autonomic neuropathy and reduced preload sensitivity - **Digoxin** binds to amyloid fibrils, potentially causing toxicity at therapeutic levels **Diuretic management** remains the cornerstone of symptomatic therapy. Given this patient’s diuretic resistance: - Consider IV diuretic challenge (gut edema from RA pressure of 23 impairs oral absorption)- he desired to try home therapy - Add metolazone for sequential nephron blockade- will reassess response next week and closely follow to ensure we dont cause hemodynamic collapse - Serial large-volume paracentesis may be necessary as a bridge or ongoing palliative strategy ### 6c. Emerging and Investigational Therapies: From Stabilization to Cure? The ATTR-CM therapeutic landscape is evolving rapidly from disease *stabilization* toward potential disease *reversal* — a trajectory that raises the question of whether “cure” is achievable. **Current State: Stabilization, Not Cure** It is important to set expectations precisely: **no currently approved therapy cures ATTR-CM**. Tafamidis and acoramidis are TTR stabilizers — they prevent further tetramer dissociation and slow disease progression, but they do not remove amyloid fibrils already deposited in the myocardium. The ATTR-ACT trial demonstrated that tafamidis reduced 30-month mortality from 42.9% to 29.5% (NNT ~8), and the ATTRibute-CM trial showed acoramidis reduced the composite of death or cardiovascular hospitalization by 35% (7,8). These are meaningful, life-extending benefits, but the disease continues to progress — albeit more slowly — and patients are not restored to normal cardiac function. Patients require lifelong therapy, and the amyloid burden already present in the myocardium remains. **Gene Silencing: Turning Off Production** RNA interference (RNAi) and antisense oligonucleotide (ASO) therapies reduce hepatic TTR production by 80–90%, effectively eliminating the supply of new amyloid precursor protein. Vutrisiran (Alnylam), an RNAi agent administered subcutaneously every 3 months, demonstrated positive cardiovascular outcomes in the HELIOS-B trial with a 28% reduction in the composite of all-cause mortality and recurrent cardiovascular events (10). CRISPR-Cas9 in vivo gene editing (NTLA-2001/nexiguran ziclumeran, Intellia) has shown greater than 90% sustained TTR knockdown after a single intravenous dose — potentially a one-time treatment that permanently silences TTR production (1,11). These approaches stop new amyloid formation but, like stabilizers, do not actively remove existing deposits. The theoretical advantage is that if production is halted completely, the body’s native clearance mechanisms may gradually resorb deposited fibrils over time, though this has not been definitively demonstrated in clinical trials. **Amyloid Removal: The True Frontier of “Cure”** The most exciting development is the emergence of therapies designed to **actively remove deposited amyloid fibrils from the myocardium** — the closest approach to actual disease reversal: **Investigational amyloid depletion:** The [NI006 phase 1 trial (2023)](https://pubmed.ncbi.nlm.nih.gov/37212440/) enrolled 40 patients with ATTR cardiomyopathy. At doses of at least 10 mg/kg, imaging measures of amyloid burden appeared to decrease during follow-up. These surrogate observations and initial safety findings require confirmation in larger trials; clinical benefit and reversal of heart failure were not established by this study. [Fontana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37285532/) described three patients with spontaneous regression of ATTR cardiomyopathy and antibodies that bound amyloid. This small observational report supports investigation of immune-mediated clearance; it does not establish a reproducible treatment or prove the mechanism of recovery. **Realistic Assessment: Can ATTR-CM Be Cured?** Disease-modifying ATTR treatments can slow progression, while amyloid-depleting antibodies remain an active research approach. A small phase 1 imaging signal does not establish functional cure or a timetable for its availability. Treatment decisions should use demonstrated clinical outcomes and current regulatory indications. For patients like ours, diagnosed with advanced disease (CI 1.15, RA 23), the immediate goal is stabilization and symptom management with a TTR stabilizer. However, if amyloid removal therapies reach clinical availability within the next several years, the possibility of meaningful cardiac recovery exists — particularly given that congestive hepatopathy and cardiac ascites are hemodynamically driven and potentially reversible if the underlying cardiac dysfunction improves. | Therapeutic Class | Mechanism | Status | “Cure” Potential | |----|----|----|----| | TTR stabilizers (tafamidis, acoramidis) | Prevent tetramer dissociation | FDA-approved | No — slows progression, does not remove deposits | | Gene silencers (vutrisiran, patisiran) | Reduce hepatic TTR production 80–90% | Approved (polyneuropathy); HELIOS-B positive for CM | Partial — stops production; native clearance may slowly reduce deposits | | CRISPR gene editing (NTLA-2001) | Permanent TTR gene knockdown (\>90%) | Phase 2/3 | Partial — single dose, permanent production halt | | Anti-amyloid antibodies (NI006) | Phagocytic removal of deposited fibrils | Phase 3 | Highest — direct amyloid removal demonstrated on imaging | | Combination (stabilizer/silencer + depleter) | Halt production + remove deposits | Theoretical/preclinical | Greatest — addresses both supply and accumulated burden | ### 6d. Multidisciplinary Care The 2023 ACC Expert Consensus Decision Pathway on Cardiac Amyloidosis emphasizes comprehensive multidisciplinary care including cardiology, hematology (if AL concern), neurology (for neuropathy screening), genetics, nephrology, and palliative care (9). Given this patient’s renal implications from low cardiac output, nephrology involvement remains essential for managing cardiorenal physiology and diuretic optimization. ------------------------------------------------------------------------ ## 7. Nephrology-Specific Considerations ### Cardiorenal Syndrome This patient exemplifies **Type 1 cardiorenal syndrome** — acute/chronic cardiac dysfunction leading to renal impairment. The cardiac index of 1.15 L/min/m² produces critical renal hypoperfusion, which: - Limits diuretic delivery to the nephron - Activates RAAS and sympathetic nervous system - Promotes sodium and water retention - Creates the diuretic resistance observed clinically ### Renal Amyloid Deposition While cardiac involvement dominates in ATTRwt, renal TTR amyloid deposition can occur and should be monitored. SGLT2 inhibitors (dapagliflozin) may provide both renal protection and mild diuretic benefit, though their hemodynamic effects require monitoring in low-output states. ### Monitoring - Serial creatinine and electrolytes during diuretic titration - Urine protein assessment for renal amyloid involvement - Medication dose adjustments for renal function ------------------------------------------------------------------------ ## 8. Summary and Teaching Points This case illustrates how cardiac amyloidosis can masquerade as primary liver disease, leading clinicians through a series of diagnostic red herrings before the unifying diagnosis emerges. The key teaching points are: 1. **EF is a fraction, not a measure of cardiac output.** In restrictive cardiomyopathy, a preserved EF can mask critically low cardiac output. When the clinical picture is worse than the echo suggests, pursue invasive hemodynamic assessment. 2. **CT “cirrhosis” requires clinical correlation.** Congestive hepatopathy can produce imaging findings indistinguishable from true cirrhosis. When there are no risk factors for liver disease and synthetic function is preserved, question the radiographic diagnosis. 3. **Ascitic fluid protein is a window into sinusoidal physiology.** High-protein ascites (≥ 2.5 g/dL) with high SAAG (≥ 1.1) points to cardiac congestion through intact sinusoidal fenestrations rather than cirrhotic capillarization. 4. **The INR on anticoagulation is not a measure of liver function.** An INR of 4.0 on warfarin reflects pharmacologic vitamin K antagonism, not hepatic synthetic failure. This distinction prevents misclassification of cardiac congestion as decompensated cirrhosis and artificially inflated MELD scores. In anticoagulated patients, rely on albumin and factor V for synthetic function assessment. 5. **Massive ascites with minimal pedal edema suggests cardiac, not cirrhotic, etiology.** Preferential splanchnic fluid accumulation with 5.7L rapid reaccumulation and dry legs is a characteristic pattern of right heart failure from restrictive cardiomyopathy — not a finding that excludes cardiac disease. 6. **Diuretic resistance quantifies the hemodynamic severity.** When bumetanide 4 mg PO BID (equivalent to ~320 mg furosemide daily) plus dapagliflozin and spironolactone cannot prevent ascites reaccumulation, the problem is not inadequate diuretic dosing — it is inadequate cardiac output and overwhelming venous congestion. Escalation requires addressing the hemodynamic driver, not simply increasing the diuretic dose. 7. **Think amyloid in elderly patients with HFpEF.** Particularly in males over 65 with unexplained HFpEF, increased wall thickness, or clinical features disproportionate to echo findings. ATTR-CM is underdiagnosed and now treatable. 8. **Interpret scintigraphy alongside monoclonal testing.** The negative PYP scan and positive lambda screen redirected evaluation toward a plasma-cell disorder and possible AL amyloidosis. Tissue confirmation and typing remain necessary. Neither a monoclonal protein alone nor a negative PYP scan establishes AL. 8b. **AL cardiac amyloidosis kills faster than ATTR.** Median survival without treatment at Mayo Stage IIIB is 4–6 months. This case ended in death before treatment could begin — a direct consequence of the time required to complete the diagnostic algorithm. In any patient with clinical features of cardiac amyloidosis, the full diagnostic panel (free light chains, serum and urine immunofixation, PYP scintigraphy) should be initiated simultaneously, not sequentially. 1. **Treatment depends on amyloid type and disease stage.** Stabilizers and gene-silencing approaches have demonstrated benefits in selected ATTR populations. AL treatment targets the responsible plasma-cell clone. Amyloid-depleting antibodies require further outcome evidence; cure should not be promised. ------------------------------------------------------------------------ > **Clinical Pearl:** When you encounter a patient with ascites, always ask three questions: (1) Is the SAAG high or low? (2) Is the fluid protein high or low? (3) Does the clinical context match? The combination of high SAAG + high protein should immediately prompt evaluation for cardiac disease, hepatic venous outflow obstruction, or other non-cirrhotic causes of portal hypertension. ------------------------------------------------------------------------ ------------------------------------------------------------------------ ## 6e. AL Amyloidosis Without Nephrotic Syndrome: The Cardiotrophic Lambda Phenotype ### Actual Free Light Chain and Monoclonal Protein Results | Test | Result | Reference / Threshold | Significance | |----|----|----|----| | Kappa free light chain | 5.31 mg/dL (53.1 mg/L) | 3.3–19.4 mg/L | Mildly elevated | | Lambda free light chain | 28.5 mg/dL (285 mg/L) | 5.7–26.3 mg/L | Markedly elevated | | Kappa/Lambda FLC ratio | 0.1863 | 0.26–1.65 | Markedly suppressed — confirms clonal lambda excess | | M-protein isotype flag | Positive (A) — IgA lambda | — | Tiny intact IgA lambda monoclonal protein | | M-protein GL | \<0.010 g/dL | — | Essentially undetectable as intact immunoglobulin | | QMPTS Interpretation | See Comments | — | Mass spectrometry confirmation of lambda light chain | **dFLC Calculation (the number that actually matters for staging):** > dFLC = Involved FLC (lambda) − Uninvolved FLC (kappa) = 285 − 53.1 = **231.9 mg/L** The Mayo AL staging system uses dFLC ≥ 180 mg/L as one of its staging criteria. Mr. Felton’s dFLC of **232 mg/L exceeds this threshold** — meeting the criterion for advanced cardiac AL staging — despite the M-protein being so small it barely registered on immunofixation (\<0.010 g/dL). This perfectly illustrates the cardinal principle: **the M-protein level is irrelevant; the dFLC is the clinically actionable number.** **Urine Studies — A Critical Nuance:** | Test | Result | Interpretation | |----|----|----| | Microalbumin/Creatinine ratio | 139 mg/g creat (H) | Microalbuminuria range — true glomerular leak | | Protein/Creatinine ratio | 0.73 (H) | Mildly elevated — not normal, not nephrotic | | Urine protein (timed) | 29 mg/dL | Low absolute value | | Urine microalbumin | 212.5 mg/L | Elevated | > ⚠️ **Correction to Earlier Characterization:** The protein/creatinine ratio of **0.73 is not normal** (normal \< 0.2). The microalbumin/creatinine ratio of **139 mg/g** confirms true glomerular leak, not isolated tubular proteinuria. Mr. Felton’s kidneys were not perfectly silent — they were whispering while his heart was screaming. However, a P/Cr of 0.73 is far below nephrotic range (\> 3.5), and the clinical presentation was dominated entirely by the cardiac syndrome. Early renal involvement was present but subclinical, likely reflecting either very early glomerular lambda deposition or hemodynamic injury to the glomerular filtration barrier from cardiorenal syndrome — or both. **PTH 267 pg/mL (elevated):** Consistent with secondary hyperparathyroidism from CKD driven by cardiorenal syndrome (CI 1.15 → renal hypoperfusion → reduced GFR → PTH elevation). Not a feature of amyloidosis per se. ------------------------------------------------------------------------ Mr. Felton had **normal serum albumin (4.0 g/dL), mildly elevated protein/creatinine ratio (0.73), and microalbuminuria (139 mg/g)** — subclinical early renal involvement present on careful review, but no nephrotic syndrome, no significant proteinuria clinically, and renal findings entirely overshadowed by the cardiac presentation. This is clinically important for two reasons: it correctly argued against cirrhosis (preserved hepatic synthetic function), but it could simultaneously have been misread as arguing *against* AL amyloidosis under the common heuristic that “myeloma-related amyloid causes nephrotic syndrome.” That heuristic is wrong and potentially lethal. ### How Common Is Cardiac-Predominant AL Without Renal Involvement? Approximately **20–30% of AL amyloidosis patients** present with predominant or isolated cardiac involvement and minimal to no renal manifestation. The distribution is heavily skewed by light chain type. **Lambda AL amyloidosis** — this patient’s subtype — is disproportionately cardiotrophic compared to kappa AL, where renal involvement (nephrotic syndrome, renal insufficiency) is more prominent. Large cohort studies from the Boston University Amyloidosis Center and the UK National Amyloidosis Centre (London) consistently demonstrate that lambda-predominant disease has a significantly higher rate of isolated cardiac phenotype. ### Why Lambda Light Chains Are Cardiotrophic Tissue tropism in AL amyloidosis is determined by the **variable domain sequence of the light chain** — specifically the CDR1 and CDR3 loops, which dictate fibril conformation and the physicochemical affinity of the misfolded protein for different tissue microenvironments. Lambda light chains encoded by certain germline variable region gene segments show preferential cardiac tropism: - **Vλ1 and Vλ6 gene segments** → strongly associated with cardiac amyloidosis, often with minimal renal involvement - **Vλ2 and Vλ3 gene segments** → more nephrotrophic; higher rates of glomerular deposition and nephrotic syndrome - **Kappa light chains** → more commonly nephrotrophic overall; isolated cardiac kappa AL is relatively uncommon In cardiotrophic lambda disease, the fibrils preferentially deposit in the **myocardial interstitium, conduction system, autonomic nerves, and intramural coronary vasculature** — producing restrictive cardiomyopathy, arrhythmia substrate, and autonomic neuropathy — while largely sparing the glomerular mesangium and capillary loops. The result is massive cardiac amyloid burden with an essentially normal urinalysis. ### Why Mr. Felton’s Kidneys Were Not Normal — Just Not Amyloid-Damaged It is important to distinguish the *cause* of any renal dysfunction in this patient. His renal impairment, if present, was driven by **cardiorenal syndrome** (Type 1) — renal hypoperfusion from CI 1.15 L/min/m² and renal venous congestion from RA pressure of 23 mmHg — not from glomerular amyloid deposition. The absence of proteinuria confirms that the glomerular filtration barrier was structurally intact. His kidneys were hemodynamically compromised bystanders, not amyloid targets. ### The Sixth Red Herring: Absent Nephrotic Syndrome > ⚠️ **Warning: Red Herring \#6 — “No Nephrotic Syndrome, Therefore Not AL Amyloidosis.”** This is a well-documented cognitive error. The absence of nephrotic syndrome should **never** be used to lower clinical suspicion for AL amyloidosis in a patient with unexplained restrictive cardiomyopathy. Cardiac-predominant lambda AL amyloidosis with a normal urinalysis is a recognized, distinct phenotype that constitutes up to 25–30% of AL amyloidosis presentations. In this patient, the preserved albumin correctly helped exclude cirrhosis — but it provided no reassurance against the diagnosis that ultimately killed him. > **Clinical Pearl:** When evaluating a patient for cardiac amyloidosis, the free light chain assay and immunofixation electrophoresis should be ordered **regardless of renal function and regardless of whether nephrotic syndrome is present.** The monoclonal protein screen tests for the clonal plasma cell process — not its renal consequences. A lambda-predominant clone can devastate the heart while the kidneys remain clinically silent. ------------------------------------------------------------------------ ## 9. Clinical Outcome: Patient Death — March 4, 2026 > 🟥 **Patient Deceased — March 4, 2026** ### Circumstances of Death Dennis Felton (DOB 5/31/1950) died on **March 4, 2026**, while undergoing a staging FDG-PET scan as part of his AL (lambda) amyloidosis workup. The cause of death was **sudden cardiac arrest**. Resuscitation efforts were unsuccessful. He had not received disease-modifying therapy for the reported AL diagnosis at the time of death. The documented testing included positive lambda serum and urine immunofixation and negative PYP scintigraphy, with hematology consultation pending. Those findings warrant further evaluation; they do not independently establish histologic amyloid type. ### Clinicopathologic Correlation His death was hemodynamically predictable, even if its timing was tragic. The right heart catheterization had established: - **Cardiac index 1.15 L/min/m²** — cardiogenic shock-range forward output - **RA pressure 23 mmHg** — severe right-sided congestion - **SvO₂ 65%** — tissue oxygen extraction at the lower limit of compensated reserve - **Forrester Profile C** — the hemodynamic subset with the highest mortality Patients with AL cardiac amyloidosis at this stage of hemodynamic compromise are at extreme risk for malignant arrhythmia. The amyloid-infiltrated myocardium creates a substrate for ventricular tachycardia and ventricular fibrillation through: - **Mechanical stretch** from chronically elevated filling pressures activating stretch-sensitive ion channels - **Autonomic neuropathy** — a hallmark of systemic AL amyloidosis — which impairs adrenergic regulation and increases arrhythmia susceptibility - **Patchy amyloid deposition** creating heterogeneous conduction velocity and refractory periods — the electrophysiologic substrate for reentrant ventricular arrhythmia - **Ischemia from microangiopathy** as amyloid deposits compress intramural coronary vasculature The physiologic stress of lying still in a PET scanner — with positioning, breath-holding, and even mild sedation or anxiety — may have been sufficient to tip an already marginal hemodynamic state into the terminal event. ### The Question of ICD / CRT This case raises the difficult and controversial question of implantable cardioverter-defibrillator (ICD) placement in AL cardiac amyloidosis. The current evidence-based perspective: - **ICDs are generally NOT recommended in AL cardiac amyloidosis** per multiple society guidelines and expert consensus. The predominant mode of death in advanced AL cardiac amyloidosis is **electromechanical dissociation (EMD/PEA)** — not shockable ventricular fibrillation. ICDs cannot treat EMD. - A 2022 analysis from the Boston University amyloidosis center found that among AL patients who received ICDs, fewer than 30% had shockable rhythms as their terminal event; the majority died from non-shockable cardiac arrest or progressive hemodynamic failure. - However, **some patients with AL amyloidosis do die from VT/VF** — particularly early in the disease course when hemodynamics are still partially compensated. There is no reliable way to prospectively identify which patients will have shockable vs. non-shockable terminal arrhythmias. - In this patient’s case, with a CI of 1.15 and severe hemodynamic compromise, the most likely mechanism of sudden death was **PEA** from hemodynamic collapse, though VF cannot be excluded without the resuscitation rhythm record. > **Clinical Pearl:** In AL cardiac amyloidosis, sudden cardiac death risk is high, but ICD placement does not reliably prevent it because EMD/PEA is the dominant mechanism. Wearable defibrillators may have a role as a bridge during the period of hematologic treatment response, but their utility is unproven. This remains an active area of clinical controversy. ### Reflections on the Diagnostic Journey This case spanned a diagnostic odyssey from presentation with what appeared to be cirrhotic ascites to the eventual confirmation of AL (lambda) cardiac amyloidosis — a journey that illustrated nearly every major pitfall in the diagnosis of infiltrative cardiomyopathy: 1. CT “cirrhosis” from congestive hepatopathy 2. Preserved EF masking cardiogenic shock-range hemodynamics 3. The initial diagnostic misdirection toward ATTR before the monoclonal screen revealed the correct etiology 4. The pivotal role of the right heart catheterization in exposing what the echocardiogram concealed 5. The fatal time compression between diagnosis confirmation and the opportunity to initiate treatment For AL cardiac amyloidosis at Mayo Stage IIIB, the window between diagnosis and death is measured in weeks to months. Diagnostic delays — including the time required to obtain referral PYP scintigraphy, await free light chain results, and schedule hematology consultation — consumed critical time that in retrospect may have foreclosed the possibility of treatment. The case is a powerful argument for simultaneously ordering the full amyloid diagnostic panel from the first clinical encounter, not sequentially. > **In Memoriam:** Dennis Felton, born May 31, 1950 — died March 4, 2026. His case is preserved in this educational record as a testament to the diagnostic challenges of cardiac amyloidosis and the unforgiving hemodynamic consequences of delayed diagnosis. ------------------------------------------------------------------------ ## References 1. Kittleson MM, Maurer MS, Ambardekar AV, et al. Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association. *Circulation*. 2020;142(1):e7-e22. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32476490/) 2. Ruberg FL, Grogan M, Hanna M, et al. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. *J Am Coll Cardiol*. 2019;73(22):2872-2891. [PubMed](https://pubmed.ncbi.nlm.nih.gov/31171094/) 3. Lane T, Fontana M, Martinez-Naharro A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. *Circulation*. 2019;140(1):16-26. [PubMed](https://pubmed.ncbi.nlm.nih.gov/31109193/) 4. Kittleson MM, Ruberg FL, Ambardekar AV, et al. 2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis. *J Am Coll Cardiol*. 2023;81(11):1076-1126. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36697326/) 5. Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. *Hepatology*. 2013;57(4):1651-1653. [PubMed](https://pubmed.ncbi.nlm.nih.gov/23463403/) 6. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. *Circulation*. 2016;133(24):2404-2412. [PubMed](https://pubmed.ncbi.nlm.nih.gov/27143678/) 7. Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. *N Engl J Med*. 2018;379(11):1007-1016. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30145929/) 8. Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. *N Engl J Med*. 2024;390(2):132-142. [PubMed](https://pubmed.ncbi.nlm.nih.gov/38197816/) 9. Simonetto DA, Liu M, Kamath PS. Portal hypertension and related complications: diagnosis and management. *Mayo Clin Proc*. 2019;94(4):714-726. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30947834/) 10. Fontana M, Berk JL, Gillmore JD, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy (HELIOS-B). *N Engl J Med*. 2025;392(1):33-44. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39213194/) 11. Garcia-Pavia P, aus dem Siepen F, Donal E, et al. Phase 1 trial of antibody NI006 for depletion of cardiac transthyretin amyloid. *N Engl J Med*. 2023;389(3):239-250. [PubMed](https://pubmed.ncbi.nlm.nih.gov/37212440/) 12. Rangaswami J, Bhalla V, Blair JEA, et al. Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. *Circulation*. 2019;139(16):e840-e878. [PubMed](https://pubmed.ncbi.nlm.nih.gov/30852913/) 13. Ladefoged B, Dybro A, Povlsen JA, et al. Diagnostic delay in wild type transthyretin cardiac amyloidosis — a clinical challenge. *Int J Cardiol*. 2020;304:138-143. [PubMed](https://pubmed.ncbi.nlm.nih.gov/32033783/) 14. Wechalekar AD, Fontana M, Quarta CC, Liedtke M. AL amyloidosis for cardiologists: awareness, diagnosis, and future prospects: state-of-the-art review. *JACC CardioOncol*. 2022;4(4):427-441. [PubMed](https://pubmed.ncbi.nlm.nih.gov/36444232/) 15. Shchendrygina A, Mewton N, Niederseer D, et al. Cardiac amyloidosis screening and management in patients with heart failure with preserved ejection fraction: an international survey. *Am J Cardiol*. 2024;236:42-48. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39481586/) ------------------------------------------------------------------------ ## See Also **Cardiology & Heart Failure:** - Cardiology Hub — heart failure overview and specialized topics - Heart Failure with Reduced Ejection Fraction (HFrEF) - HFpEF Diagnostic Criteria 2025 - Aldosterone Blockade - Risks and Benefits - Flash Pulmonary Edema Review **Cardiorenal Syndrome:** - Cardiorenal Hub — cross-links between cardiac and renal pathophysiology - Cardiorenal Syndrome Overview - Heart Failure Comprehensive Report - Cardiorenal GDMT (Guideline-Directed Medical Therapy) **Hepatorenal Intersection:** - Hepatorenal Index — hepatic and renal dysfunction - Hepatopulmonary Syndrome Review **Hematology & Oncology (Amyloidosis):** - MGUS vs MM: Scoring Systems & MASS-FIX Interpretation — AL amyloidosis staging (Mayo 2004/2012), lambda light chain amyloidogenicity, MASS-FIX glycosylation as AL risk marker, dFLC thresholds and unit conversions. ------------------------------------------------------------------------ *Case prepared for educational purposes. Patient details have been modified to protect confidentiality. All clinical decisions should be made in consultation with appropriate specialists.* *This educational review was prepared by the Medical Associates Department of Nephrology in collaboration with the University of Illinois College of Medicine at Peoria, the University of Dubuque Physician Assistant Program, and the UDPA Butler School of Medicine. It is intended for use in clinical education and does not constitute individualized medical advice.* *© 2026 Medical Associates Department of Nephrology — Cardiorenal Education Series* ------------------------------------------------------------------------ Felton, Dennis 5/31/50 118718411 ### Also on this topic The same subject at other levels of depth. - **Clinical Mastery deep dive:** [The Hidden Cardiomyopathy: Diagnostic Challenges in AL (Lambda) Cardiac Amyloidosis](https://urinenephrology.org/mastery/paraprotein/cardiac-amyloidosis-diagnosis.html) --- [Website version](https://urinenephrology.org/case-reports/cardiac-amyloidosis-diagnostic-challenges.html) · Markdown synchronized October 3, 2026.